Pheast Therapeutics is a clinical-stage biotech engineering the innate immune system to attack cancer. Its lead drug, PHST001, is an anti-CD24 macrophage checkpoint inhibitor designed to flip the 'don't eat me' signal that solid tumors use to hide from the body's first-line defenders.
OncoC4, Inc. is a Rockville, Maryland clinical-stage biopharmaceutical company building first-in-class and best-in-class antibody therapies for hard-to-treat cancers and Alzheimer's disease. Founded by immunologists Yang Liu and Pan Zheng, the company discovered the innate immune checkpoint CD24-Siglec-10 and is advancing a pipeline led by gotistobart (ONC-392), a next-generation anti-CTLA-4 antibody partnered with BioNTech, alongside SIGLEC10, PD-1/VEGF, and CD24-targeting programs.
Yang Liu is a cancer immunologist turned serial biotech founder who chairs and runs OncoC4, the Rockville, Maryland company developing next-generation immune checkpoint antibodies. After decades as an endowed professor at NYU, Ohio State, Michigan, and beyond, he co-founded OncoImmune (acquired by Merck for $425M) and then OncoC4, whose lead anti-CTLA-4 antibody gotistobart is in late-stage development with BioNTech. He left full-time academia to take his own discoveries from the bench into patients.